Current management of heparin-induced thrombocytopenia

Expert Review of Hematology

Volumn 8, Issue 6, 2015, Pages 837-849

  Cosmi, Benilde ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

argatroban; bivalirudin; danaparoid; ELISA; heparin; low molecular weight heparin; platelet factor 4; serotonin release assay; thrombocytopenia; thrombosis

Indexed keywords

ARGATROBAN; DANAPAROID; FONDAPARINUX; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRULOG; IMMUNOGLOBULIN G ANTIBODY; THROMBIN; THROMBOCYTE FACTOR 4;

ANTIBODY DETECTION; CHILD; CLINICAL FEATURE; DISEASE ACTIVITY; FREQUENCY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY DIAGNOSIS; META ANALYSIS (TOPIC); PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PLATELET AGGREGATION ASSAY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; CHEMICALLY INDUCED; PATHOLOGY;

HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 84947614854     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2015.1087845     Document Type: Review

References (74)

1. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011; 9(Suppl 1):105-17
2. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008;112:2607-16
3. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958;76:219-25
4. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973;136:409-16
5. Greinacher A, Delcea M. Another surprising finding in heparin-induced thrombocytopenia-eat big. J Thromb Haemost 2015;13:1414-15
6. Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2015;373:252-61
7. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006;107:2346-53
8. Rao AK, Niewiarowski S, James P, et al. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 1983;61:1208-14
9. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-6
10. Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008;122:211-20
11. Krauel K, Weber C, Brandt S, et al. Platelet factor 4 binding to lipid A of Gram negative bacteria exposes PF4/heparin-like epitopes. Blood 2012;120:3345-52
12. Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 2014;124:2442-9
13. Nguyen TH, Greinacher A, Delcea M. Quantitative description of thermodynamic and kinetic properties of the platelet factor4/heparin bonds. Nanoscale 2015;7: 10130-9
14. Sauerborn M, van Beers MM, Jiskoot W, et al. Antibody response against Betaferon in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory. J Clin Immunol 2013;33:255-63
15. Prechel MM, Walenga JM. Complexes of platelet factor 4 and heparin activate Toll-like receptor 4. J Thromb Haemost 2015;13:665-70
16. Zheng Y, Wang AW, Yu M, et al. B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood 2014;123:931-4
17. Joglekar M, Khandelwal S, Cines DB, et al. Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages. J Thomb Haemost 2015;13: 1416-27
18. Bakchoul T, Zöllner H, Amiral J, et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood 2013;121:2821-7
19. Karnes JH, Cronin RM, Rollin J, et al. A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb Haemost 2015;113:772-81
20. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin induced thrombocytopenia. Blood 1994;84: 3691-9
21. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-16
22. Linkins LA, Dans AL, Moores LK, et al. Treatment and Prevention of Heparin-Induced Thrombocytopenia Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e495S-e530S
23. Arepally G, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-17
24. Zalcberg JR, McGrath K, Dauer R, Wiley JS. Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation [Letter]. Br J Haematol 1983;54:655-7
25. Warkentin T E, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135: 502-6
26. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008;121: 632-6
27. Padmanabhan A, Jones CG, Bougie DW, et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood 2015;125:155-61
28. Linkins LA. Heparin induced thrombocytopenia. BMJ 2015;350:g7566
29. Obeng EA, Harney KM, Moniz T, et al. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr 2015;166:144-50
30. Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin induced thrombocytopenia: second edition. Br J Haemat 2012;159:528-40
31. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65
32. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012;120:4160-7
33. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert probability (HEP) Score: a novel pre-test probability model for heparin induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642-50
34. Messmore HL, Fabbrini N, Bird Ml, et al. Simple scoring system for early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2011;17:197-201
35. Lillo-Le LA, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004;2:1882-8
36. Hicks LK, et al. Five hematologic tests and treatments to question. Blood 2014;124: 3524-8
37. Bakchoul T, Zöllner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. Int J Lab Hem 2014;36: 296-305
38. Chan C, Woods CJ, Warkentin TE, et al. The role for optical density in heparin-induced thrombocytopenia: A cohort study. Chest 2015;148:55-61
39. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin release assay. Am J Hematol 2015;90:564-72
40. Linkins LA, Bates SM, Lee AYY, et al. Combination of 4Ts score and PF4/HPaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood 2015;126: 597-603
41. Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 2013;368:737-44
42. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-6
43. Krauel K, Hackbarth C, Furll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012;119:1248-55
44. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006;129:1407-16
45. Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125:924-9
46. Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)-findings from the GerHIT multi-centre registry study. Thromb Res 2014;134:29-35
47. Bhatt VR, Aryal MR, Armitage JO. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 2013;368:2334
48. Dhakal P, Giri S, Pathak R, Bhatt VR. Heparin Reexposure in patients with a history of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2015. [Epub ahead of print]
49. Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are re-exposed to heparin. Blood 2014;123:2485-93
50. Alatri A, Armstrong AE, Greinacher A, et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. Thromb Res 2012;129:426-33
51. Dyke CM, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thor Sur 2007;84:836-9
52. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thor Sur 2007;83:572-7
53. Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010;110: 30-5
54. Warkentin TE, Sheppard JAI, Chu FV, et al. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood 2015;125:195-8
55. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemos 2005;93:63-9
56. Young G, Boshkov LK, Sullivan JE, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer 2011;56:1103-9
57. Argueta-Morales IR, Olsen MC, DeCampli WM, et al. Alternative anticoagulation during cardiovascular procedures in pediatric patients with heparin-induced thrombocytopenia. J Extra Corpor Technol 2012;44:69-74
58. Miyares MA, Davis KA. Direct-acting oral anticoagulants as emerging treatment options for heparin induced thrombocytopenia. Ann Pharmacoth 2015;49:735-9
59. Sharifi M, Bay C, Vajo Z, et al. New oral anticoagulants in the treatment of heparin induced thrombocytopenia. Thromb Res 2015;135:607-9
60. Sartori M, Favaretto E, Cini M, et al. Rivaroxaban in the treatment of heparin-induced thrombocytopenia. J Thromb Thrombolysis 2015. [Epub ahead of print]
61. Rivaroxaban for treatment of patients with suspected or confirmed heparin-induced thrombocytopenia. Available from: https:// clinicaltrials.gov/ct2/show/NCT01598168
62. McKenzie SE, Sachais BS. Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. Curr Opin Hematol 2014;21:380-7
63. Nellen V, Sulzer I, Barizzi G, et al. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1291 patients. Haematologica 2012;97: 89-97
64. Available from: www.ema.europa.eu/docs/ en-GB/document-library/ EPAR-Product-Information/human/ 000403/WC500027746.pdf
65. Retrospective registry of patients with acute heparin-induced thrombocytopenia type II. Available from: https://clinicaltrials.gov/ct2/ show/NCT01304238
66. Retrospective study of patients who were treated with fondaparinux pre-, peri-and/or postpartum for prophylaxis or treatment of venous thromboembolism (FondaPPP). Available from: https://clinicaltrials.gov/ct2/ show/NCT01004939
67. Fondaparinux for the treatment of heparin-induced thrombocytopenia (HIT). Available from: https://clinicaltrials.gov/ct2/ show/NCT00673439
68. Tvito A, Bakchoul T, Rowe JM, et al. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Am J Hematol 2015;90:675-8
69. Cuker A, Rux AH, Hinds JL, et al. Novel diagnostic assays for heparin-induced thrombocytopenia. Blood 2013;121: 3727-32
70. Nazi I, Arnold DM, Smith JW, et al. FcgammaRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. J Thromb Haemost 2013;11:1146-53
71. Medvedev N, Palankar R, Krauel K, et al. Micropatterned array to assess the interaction of single platelets with platelet factor 4-heparin-IgG complexes. Thromb Haemost 2014;111:862-72
72. Scarparo P, Lombardi AM, Duner E, et al. Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms. Platelets 2013;24:362-8
73. Rollin J, Pouplard C, Gratacap MP, et al. Polymorphisms of protein tyrosine phosphatase CD148 influence FcgammaRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood 2012;120: 1309-16
74. Abraham S, Andre P, Zhou Y, et al. Differential expression of microRNAs accompanies differential reactivity via platelet FcgammaRIIa in humans and transgenic mice. Blood 2012;120:2165a